New York City, NY, 28 November, 2019/ 24 Market Reports: It is estimated for the global bone densitometer market to reach USD 313 million by 2024 from USD 244 million in 2019, at a CAGR of 4.6% during the forecast period of 2019 to 2024. The increasing prevalence of osteoporosis and the rising geriatric population is driving the growth for the market during the forecast period. It is estimated for factors such as the high cost of bone densitometers and low awareness to hamper the growth of the market during the forecast period.
Dual-energy X-ray bone absorptiometry (DEXA) scanners and peripheral bone densitometers are the segmentation for the bone densitometer market based on type. It is estimated for the DEXA scanners segment to account for the highest share in the market during the forecast period registering the highest CAGR in the market. The advantages of DEXA scanners over peripheral bone densitometers are propelling the growth of the market. Moreover, results obtained from DEXA scanners can be interpreted using WHO scores for greater accuracy, which accounts for their high use.
The market has been segmented into osteoporosis & osteopenia diagnosis, body composition measurement, rheumatoid arthritis diagnosis, cystic fibrosis diagnosis, and chronic kidney disease diagnosis based on application. During the forecast period, it is estimated for the osteoporosis & osteopenia diagnosis segment to grow at the highest CAGR. Growing geriatric population and the subsequent increase in the prevalence of osteoporosis, the increasing risk of osteoporosis in menopausal women, and the growing global incidence of fragility fractures are the factors boosting the growth of the segment during the forecast period.
Hospitals & speciality clinics, diagnostic & imaging centres, and other end users are the segmentation for the marker-based on end-user. During the forecast period, it is estimated for the hospitals & speciality clinics segment to account for the largest share of the market. Owing to the higher preference of patients for hospital-based treatment monitoring for diseases such as cystic fibrosis, chronic kidney diseases, and osteoporosis majority of the bone density scans are performed in hospitals.
The Asia Pacific region is estimated to grow at the highest CAGR during the forecast period. Primarily due to the rising geriatric population, increasing incidence of osteoporosis, increasing healthcare expenditure, and the growing number of hospitals and clinics the Asian countries are expected to offer significant growth opportunities for market players in the forecast period.